CORT - CORCEPT THERAPEUTICS INC

45.1
-1.240   -2.749%

Share volume: 961,743
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$46.34
-1.24
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
60%
Profitability 82%
Dept financing 3%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.30%
1 Month
34.11%
3 Months
9.20%
6 Months
-38.76%
1 Year
-30.27%
2 Year
102.24%
Key data
Stock price
$45.10
P/E Ratio 
37.29
DAY RANGE
$44.50 - $46.68
EPS 
$0.95
52 WEEK RANGE
$28.66 - $91.00
52 WEEK CHANGE
-$34.89
MARKET CAP 
3.661 B
YIELD 
N/A
SHARES OUTSTANDING 
106.374 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-28-2025
BETA 
1.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,033,572
AVERAGE 30 VOLUME 
$1,846,042
Company detail
CEO: Joseph K. Belanoff
Region: US
Website: corcept.com
Employees: 300
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.

Recent news